Evidence map›Paper›PMID 16507216›Full record

ReviewCurrent oncology reports2006

VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices.

Brian I Rini

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current oncology reports, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 14 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Brian I RiniCleveland Clinic Foundation, 9500 Euclid Avenue/Desk R35, Cleveland, OH 44195, USA. rinib2@ccf.org
Cleveland Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several molecular pathways are implicated in renal cell carcinoma (RCC) pathogenesis, including von Hippel--Lindau (VHL) gene inactivation leading to vascular endothelial growth factor (VEGF) expression. Therapeutic targeting of VEGF and related pathways has been undertaken in metastatic RCC. Substantial clinical activity has been reported for multiple agents, leading to several clinical questions regarding the optimal use of these agents. The biology, clinical results, and future considerations regarding VEGF-targeted agents in RCC are presented in this article.

Indexed as

Angiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsAxitinibBenzenesulfonatesBevacizumabCarcinoma, Renal CellChemotherapy, AdjuvantErbB ReceptorsHumansImidazolesIndazolesIndolesKidney NeoplasmsNeoplasm MetastasisAngiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsAxitinibBenzenesulfonatesBevacizumabErbB ReceptorsImidazolesIndazolesIndolesNiacinamidePhenylurea CompoundsPlatelet-Derived Growth FactorPyridinesPyrrolesSorafenibSunitinibVascular Endothelial Growth Factor AVon Hippel-Lindau Tumor Suppressor Protein

Identifiers

PMID16507216
OpenAlexW2080109637

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.